ArticleJournal of virology1994
The product of the adenovirus intermediate gene IVa2 is a transcriptional activator of the major late promoter.
Article in Journal of virology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 111 citations in OpenAlex.
- Genomic Context and Insert Orientation in the Regulation of Transgene Expression in Adenoviral Vectors.International journal of molecular sciences · 2026Review
- Mysteries of adenovirus packaging.Journal of virology · 2025Review
- Article
- Article
- Adipocyte commitment of 3T3-L1 cells is required to support human adenovirus 36 productive replication concurrent with altered lipid and glucose metabolism.Frontiers in cellular and infection microbiology · 2022Article
- Adenovirus Core Proteins: Structure and Function.Viruses · 2021Review
- Broad and Efficient Activation of Memory CD4Frontiers in immunology · 2021Article
- The adenovirus L4-22K protein regulates transcription and RNA splicing via a sequence-specific single-stranded RNA binding.Nucleic acids research · 2017Article
- Regulation of human adenovirus alternative RNA splicing by the adenoviral L4-33K and L4-22K proteins.International journal of molecular sciences · 2015Review
- Impact of adenovirus life cycle progression on the generation of canine helper-dependent vectors.Gene therapy · 2015Article
- Isolation and characterization of the DNA and protein binding activities of adenovirus core protein V.Journal of virology · 2014Article
- The repression domain of the E1B 55-kilodalton protein participates in countering interferon-induced inhibition of adenovirus replication.Journal of virology · 2013Article
- Identification and characterization of a DNA binding domain on the adenovirus IVa2 protein.Virology · 2012Article
- Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.Human gene therapy · 2012Article
- Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery.Antiviral research · 2012Article
- Role of the RNA recognition motif of the E1B 55 kDa protein in the adenovirus type 5 infectious cycle.Virology · 2011Article
- Identification of a previously unrecognized promoter that drives expression of the UXP transcription unit in the human adenovirus type 5 genome.Journal of virology · 2010Article
- Adenovirus late-phase infection is controlled by a novel L4 promoter.Journal of virology · 2010Article
- Adenovirus serotype 5 L4-22K and L4-33K proteins have distinct functions in regulating late gene expression.Journal of virology · 2009Article
- Adenovirus IVa2 protein binds ATP.Journal of virology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the course of lytic infection, the adenovirus major late promoter (MLP) is induced to high levels after replication of viral DNA has started. We had previously shown that sequence elements located downstream of the MLP start site were implicated in this late-specific transcriptional activation (DE1, between +85 and +98; DE2, between +100 and +120). Two positive transcription factors involved in this activation have been detected. DEF-A, which specifically binds to DE1 and also to the 3' portion of DE2 (DE2a), and DEF-B, which interacts with the 5' part of DE2 (DE2b). When present together, these two proteins cooperatively assemble onto the DE2 element. We now report the purification of DEF-B and show that it is identical to the product of the adenovirus IVa2 gene product. This conclusion is based on microsequence analysis of DEF-B as well as on the inhibitory effect of antibodies against IVa2 on the DNA-binding activity of DEF-B and also on DE-dependent in vitro transcription. In addition, we show that bacterially synthesized IVa2 protein binds to the DE sequences with the same specificity as DEF-B. Finally, in transfected cells, a recombinant IVa2 protein stimulates MLP activity in a DE-dependent fashion. The physiological implications of these findings are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.